Fujioka, Ken

A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management

Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C. W., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., et al. (2015) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 2,724

Recombinant Leptin for Weight Loss in Obese and Lean Adults: A Randomized, Controlled, Dose-Escalation Trial

Heymsfield, S. B., Greenberg, A. S., Fujioka, K., Dixon, R. M., Kushner, R., Hunt, T., Lubina, J. A., Patane, J., Self, B., Hunt, P., et al. (1999) · JAMA

Regulation of Appetite and ObesityPharmacology and Obesity Treatment

Cited by 1,422

Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): A multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Greenway, F. L., Fujioka, K., Plodkowski, R. A., Mudaliar, S., Guttadauria, M., Erickson, J., Kim, D. D., & Dunayevich, E. (2010) · The Lancet

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 1,036

Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes

Hollander, P., Gupta, A. K., Plodkowski, R., Greenway, F., Bays, H., Burns, C., Klassen, P., Fujioka, K., & for the COR-Diabetes Study Group (2013) · Diabetes Care

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 501

Bupropion SR Enhances Weight Loss: A 48‐Week Double‐Blind, Placebo‐ Controlled Trial

Anderson, J. W., Greenway, F. L., Fujioka, K., Gadde, K. M., McKenney, J., & O'Neil, P. M. (2002) · Obesity Research

Pharmacology and Obesity TreatmentEating Disorders and Behaviors

Cited by 315

Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study.

Hill, J. O., Hauptman, J., Anderson, J. W., Fujioka, K., O'Neil, P. M., Smith, D. K., Zavoral, J. H., & Aronne, L. J. (1999) · The American Journal of Clinical Nutrition

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 287

Follow-up of Nutritional and Metabolic Problems After Bariatric Surgery

Fujioka, K. (2005) · Diabetes Care

Bariatric Surgery and OutcomesClinical Nutrition and Gastroenterology

Cited by 260

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 244

Effect of Reversible Intermittent Intra-abdominal Vagal Nerve Blockade on Morbid Obesity: The ReCharge Randomized Clinical Trial

Ikramuddin, S., Blackstone, R. P., Brancatisano, A., Toouli, J., Shah, S. N., Wolfe, B. M., Fujioka, K., Maher, J. W., Swain, J., Que, F. G., et al. (2014) · JAMA

Bariatric Surgery and OutcomesVagus Nerve Stimulation Research

Cited by 214

Pre‐ and Postsurgery Behavioral Compliance, Patient Health, and Postbariatric Surgical Weight Loss

Toussi, R., Fujioka, K., & Coleman, K. J. (2009) · Obesity

Bariatric Surgery and OutcomesObesity and Health Practices

Cited by 196

Comparison of Combined Bupropion and Naltrexone Therapy for Obesity with Monotherapy and Placebo

Greenway, F. L., Dunayevich, E., Tollefson, G., Erickson, J., Guttadauria, M., Fujioka, K., Cowley, M. A., & for the NB-201 Study Group (2009) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 179

A randomized, double-blind, placebo-controlled study of gelesis100: A novel nonsystemic oral hydrogel for weight loss

Greenway, F. L., Aronne, L. J., Raben, A., Astrup, A., Apovian, C. M., Hill, J. O., Kaplan, L. M., Fujioka, K., Matejkova, E., Svacina, S., et al. (2019) · Obesity

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 179

Progressive Reduction in Body Weight after Treatment with the Amylin Analog Pramlintide in Obese Subjects: A Phase 2, Randomized, Placebo-Controlled, Dose-Escalation Study

Aronne, L., Fujioka, K., Aroda, V., Chen, K., Halseth, A., Kesty, N. C., Burns, C., Lush, C. W., & Weyer, C. (2007) · The Journal of Clinical Endocrinology & Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 178

The EMPOWER Study: Randomized, Prospective, Double-Blind, Multicenter Trial of Vagal Blockade to Induce Weight Loss in Morbid Obesity

The EMPOWER Study Group, Sarr, M. G., Billington, C. J., Brancatisano, R., Brancatisano, A., Toouli, J., Kow, L., Nguyen, N. T., Blackstone, R., Maher, J. W., et al. (2012) · Obesity Surgery

Bariatric Surgery and OutcomesVagus Nerve Stimulation Research

Cited by 162

Early weight loss with liraglutide 3.0 mg predicts 1-year weight loss and is associated with improvements in clinical markers

Fujioka, K., O'Neil, P. M., Davies, M., Greenway, F., C.W. Lau, D., Claudius, B., Skjøth, T. V., Bjørn Jensen, C., & P.H. Wilding, J. (2016) · Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 131

Current and emerging medications for overweight or obesity in people with comorbidities

Fujioka, K. (2015) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentBariatric Surgery and Outcomes

Cited by 76

Efficacy, dose–response relationship and safety of once‐daily extended‐release metformin (Glucophage® XR) in type 2 diabetic patients with inadequate glycaemic control despite prior treatment with diet and exercise: results from two double‐blind, placebo‐controlled studies

Fujioka, K., Brazg, R. L., Raz, I., Bruce, S., Joyal, S., Swanink, R., & Pans, M. (2005) · Diabetes Obesity and Metabolism

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 73

Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity

Smith, S. R., Fujioka, K., Gupta, A. K., Billes, S. K., Burns, C., Kim, D., Dunayevich, E., & Greenway, F. L. (2013) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentRegulation of Appetite and Obesity

Cited by 55

Improvements in health‐related quality of life over 3 years with liraglutide 3.0 mg compared with placebo in participants with overweight or obesity

Kolotkin, R. L., Smolarz, B. G., Meincke, H. H., & Fujioka, K. (2018) · Clinical Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 46

Improvements in health‐related quality of life with liraglutide 3.0 mg compared with placebo in weight management

Kolotkin, R. L., Fujioka, K., Wolden, M. L., Brett, J. H., & Bjorner, J. B. (2016) · Clinical Obesity

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 40